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Abstract
Introduction
Drug confusion is thought to be the most common type of dispensing error. Several strate-
gies can be implemented to reduce the risk of medication errors. One of these are alerts in
the pharmacy information system.
Objective
To evaluate the experiences of pharmacists and pharmacy technicians with alerts for drug
name and strength confusion.
Methods
In May 2017, a cross-sectional survey of pharmacists and pharmacy technicians was per-
formed in community pharmacies in the Netherlands using an online questionnaire.
Results
Of the 269 respondents, 86% (n = 230) had noticed the alert for drug name confusion,
and 26% (n = 67) for drug strength confusion. Of those 230, 9% (n = 20) had experienced
that the alert had prevented dispensing the wrong drug. For drug strength confusion, this
proportion was 12% (n = 8). Respondents preferred to have an alert for drug name and
strength confusion in the pharmacy information system. ‘Alert fatigue’ was an important
issue, so alerts should only be introduced for frequent confusions or confusions with seri-
ous consequences.
Conclusion
Pharmacists and pharmacy technicians were positive about having alerts for drug confu-
sions in their pharmacy information system and experienced that alerts contributed to the
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prevention of dispensing errors. To prevent alert fatigue, it was considered important not to
include all possible confusions as a new alert: the potential contribution to the prevention of
drug confusion should be weighed against the risk of alert fatigue.
Introduction
Dispensing errors occur in clinical and community pharmacy and commonly involve supply
of the wrong drug, the wrong strength and the wrong form of medication [1,2]. They occur at
an average rate of 4 in 250 prescriptions (1.6%) in pharmacies in the United States [3], and
incidences up to 45% have been reported in different pharmacy settings [4]. A study in the
Netherlands showed that 41% of all medication incidents in community pharmacies related
to information technology, were about choosing the wrong drug. One third of incidents were
associated with confusion of similar drug names and nearly half were associated with drug
strength confusion [5]. Drug strength confusion can happen when two strengths of the same
drug look alike, e.g. 3.75 mg and 0.375 mg pramipexole [6]. Drug name and strength confusion
are serious issues as they are preventable errors with potential detrimental impact on clinical
practice and patient safety [7,8].
Several strategies can be implemented at different steps in the dispensing process to reduce
the risk of medication errors because of drug confusion in pharmacies, such as the use of bar-
code scanners, Tall man lettering and alerts (Fig 1)[7,9–13]. Barcode scanners check whether
the selected drug from the shelf is the same as the selected drug on the dispensing screen [7].
Tall Man lettering highlights the differences between look-alike drug names due to use of a
combination of lower and upper case letters. The use of Tall man lettering is recommended
in several countries [14–16], although evidence of a beneficial effect for Tall Man lettering is
limited [10,17–19]. Alerts in the pharmacy information system (PIS) warn the pharmacist or
pharmacy technicians for possible drug name or strength confusion at the time of entering the
prescription in the PIS. This strategy has been implemented in Dutch community pharmacies
[20].
A concern of this intervention is ‘alert fatigue’, a state caused by too many alerts resulting
in alerts being completely ignored [21]. Since the number of potential alerts for drug name
confusion is high [22], it is important to use the alert strategically [7,21,23]. Little is known
about the effectiveness and how to use alerts for drug name and strength confusion in the PIS
and whether they are seen as useful by pharmacy technicians and pharmacists.
Objective
The aim of this study was to evaluate the experiences of pharmacists and pharmacy technicians
with the alerts for drug name and strength confusion in the Netherlands.
Methods
Setting
Pharmacy information system (PIS). The alert for drug name and drug strength confu-
sion is implemented in one of the PIS in the Netherlands: Pharmacom1, by TSS PharmaPart-
ners. This PIS is used in about 60% of the 1981 pharmacies in the Netherlands [24]. There are
no alerts for drug name or strength confusion in any other PIS or in computerized prescribed
order entry systems in the Netherlands.
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Drugs with an alert for drug name and strength confusion. In 2015, the alert for drug
name and strength confusion was revised. The selection of drugs with an alert was based on a
list of most frequently reported and/or serious incidences in the period 2010–2015 at the Cen-
tral Medication incidents Registration (CMR), and a qualitative evaluation in 9 pharmacies
Fig 1. Different types of interventions to support the notification of potential drug name and drug strength
confusion at different stages of the dispensing process in the pharmacies. DRP = drug-related problem,
PIS = pharmacy information system. 1) Accept the prescription: verify the patient and the prescription; 2) Entry of the
prescription in the PIS; 3) Asses appropriateness of the therapy: identify and resolve potential drug-related problems
and review other aspects; 4) Select and prepare the drug; 5) Labeling and check dispensed product; 6) Final check by
pharmacy technician or pharmacist; 7) Supply of the drug and patient counseling.
https://doi.org/10.1371/journal.pone.0197469.g001
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[20]. For a limited number of drugs (n = 8) an alert was implemented to prevent too many
alerts, and reduce the risk of alert fatigue. Tall man lettering was used in three of the eight
alerts for drug name confusion. For the drugs with an alert for strength confusion (5 alerts)
only the highest strengths of the drugs received an alert to prevent alert fatigue. Morphine
injections for which there was a risk of dispensing the wrong volume also received an alert
(2 alerts)[20]. The drugs with an alert for name or strength confusion are listed in Table 1.
Alert in clinical decision support. If a prescription of one of the drugs listed in Table 2
was entered in the PIS, an alert was generated in case of a first dispensing. For example, in the
case of prescription of dexamethasone, a pop-up window appeared with the text: ‘Caution for
drug name confusion: DexamethaSONe or dexamphetAMINe?’. A single click abrogated the
pop-up window and the dispensing process could be continued without interruption. The pur-
pose of these pop-up windows was therefore to gain attention of the pharmacist or pharmacy
technician. It was up to the person to act and check if the right drug or strength was selected.
Table 1. Drugs with an alert for name and strength confusion [20].
Drugs with an alert for drug name confusion
DexamethaSONe DexamphetAMINE
Tobrex (tobramycin) TobrADex (dexamethasone/tobramycin)
Fraxiparine1 (nadroparin) Fraxodi1 (nadroparin)
estrADiol Estriol
Modalim1 (ciprofibrate) Modafinil (Modiodal1)
Haloperidol injection Haloperidol decanoate injection (depot)
Povidone Povidone iodine eye drops
Hydrochlorothiazide 25 mg Hydroxyzine 25 mg
Drugs with an alert for drug strength confusion
Pramipexole 0.375 mg Pramipexole 3.75 mg
Levothyroxine 12.5 μg Levothyroxine 125 μg
Haloperidol 0.5/1 mg Haloperidol 5/10 mg
Morphine 10 mg/ml– 1 ml Morphine 10 mg/ml– 10 ml
Morphine 20 mg/ml– 1 ml Morphine 20 mg/ml– 5 ml
Desmopressin 2.5/10 μg/do Desmopressin 150 μg/do
Oxazepam 5 mg Oxazepam 50 mg
https://doi.org/10.1371/journal.pone.0197469.t001
Table 2. Pharmacist and technician’s experience with the alert for drug name and strength confusion.
Experience with the alerts. Drug name confusion
n, (%)
Strength confusion
n, (%)
Have you noticed the alert in your PIS? Yes: 230 (85.5) Yes: 67 (25.5)
How did you act when you noticed the alert?
- I checked if I had the right drug. 170 (74.6) 58 (89.2)
- I ignored the alert, because I knew I had the right drug. 35 (15.4) 3 (4.6)
- I asked a colleague to check if I had the right drug. 4 (1.8) 2 (3.1)
- I did not pay attention to the alert. 5 (2.2) 0 (0.0)
- Other. 14 (6.1) 2 (3.1)
Has this alert prevented drug confusion in your pharmacy?
- Yes. 20 (8.8) 8 (12.3)
- No, because I had the right drug. 174 (76.3) 44 (67.7)
- Unknown. 34 (14.9) 13 (20.0)
Abbreviations: PIS = pharmacy information system.
https://doi.org/10.1371/journal.pone.0197469.t002
Preventing dispensing errors by alerting for drug confusions
PLOS ONE | https://doi.org/10.1371/journal.pone.0197469 May 29, 2018 4 / 11
Study design
This was a cross-sectional survey of community pharmacists and pharmacy technicians in the
Netherlands was performed in May 2017. A questionnaire was designed in the online survey
software tool Survey Monkey (Survey Monkey, Palo Alto, CA, USA) and sent to all known e-
mail addresses of potential Pharmacom users. For commercial and privacy reasons, e-mail
addresses of Pharmacom users were not available. The collected e-mail addresses of potential
users came from (1) subscribers to the Health Base Newsletter, that informs users about news
concerning decision support and alerts in Pharmacom (n = 1234), and (2) Pharmacom users,
that participated in a 2013 questionnaire study (n = 1056)[25]. The total number of invitations
that were sent after removing duplicates (n = 2037) was higher than the estimated number of
Pharmacom users (n = 1200), as the sample could contain more people within one pharmacy
and also people not using Pharmacom. Those who did not want to participate were asked to
give their reason for non-response. In total, three reminders were sent. Two reminders as
an article in the Health Base Newsletter (1 and 4 weeks after the initial invitation), and one
reminder was sent to all e-mail addresses that had not yet responded (2 weeks after initial invi-
tation). The questionnaire was closed after 8 weeks.
This study was exempt from review by the institutional review board, since the study con-
cerned healthcare professionals and did not involve any intervention. The data were collected
anonymously and stored in accordance with privacy regulations.
Questionnaire
Baseline characteristics were limited to the function within the pharmacy and the PIS that was
used.
General questions for both name and strength confusion were: (1) have you noticed this
alert, (2) if so, how did this influence the dispensing process, (3) did the alert prevent that a
wrong drug was dispensed, (4) did the alert attract your attention, and—for drug name confu-
sion–(5) how did you experience Tall man lettering, and (6) would you like Tall man lettering
for all alerts concerning drug name confusion?
For the 15 alerts that were implemented in the PIS, respondents were asked if they preferred
to receive an alert for this confusion and if they missed any drugs with potential name or
strength confusion that should be added to the list.
Opinions about criteria to select a potential confusion as alert in the PIS were explored by
eight statements that included statements about the potential to prevent harm versus the risk
to introduce alert fatigue. For all questions, it was possible to add additional comments.
Data analysis
All results from the online questionnaire were transferred into Microsoft Excel 2010 and IBM
SPSS statistics 23.0. Frequencies and percentage, n (%), were computed. Differences between
pharmacists and pharmacy technicians were calculated using Mann-Withney U test for vari-
ables on ordinal level, and Chi-Square Goodness of Fit Test for variables on nominal level. P-
values of<0.05 were considered statistically significant. Comments on questions were ana-
lyzed and grouped if the comments were comparably. The proportion of respondents per
pharmacy was calculated, assuming that for each pharmacy one respondent was reached with
the collected e-mail addresses. Hence, the response rate per pharmacy was computed as the
number of respondents divided by the number of Pharmacom pharmacies (n = 1200).
As the aim was evaluate the experience of the alerts for confusion of drug name and
strength, respondents were asked to confirm if used the PIS Pharmacom. Those whom did not
confirm, were excluded.
Preventing dispensing errors by alerting for drug confusions
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Results
A total of 337 people responded to the invitation: 291 (86%) completed the questionnaire
study and 46 (14%) completed a non-response questionnaire in which they gave their reasons
why they did not participate in the study. The most common reasons were: 1) the respondents
had not noticed that the alert had changed (n = 23), 2) they thought the alert was good as it is
(n = 13) and 3) they had no time for answering the questionnaire (n = 10). Of the 291 partici-
pants in the questionnaire study, 22 (8%) were excluded because they did not use Pharmacom
as PIS or because the used PIS was unknown.
Of the 269 included respondents, 193 (72%) were pharmacists and 76 (28%) were pharmacy
technicians or pharmacy employees who had higher professional education at the bachelor
level. The mean response rate per pharmacy was 22.3% (269/1200). As there were no notewor-
thy differences between pharmacists and technicians, the pooled results are presented.
Experience with the alerts
Of the respondents, 86% had noticed the alert for drug name confusion in their PIS (Table 2).
The alert for drug strength confusion was noticed by 26% of the respondents. Most of the
respondents who noticed the alert checked if they had the right drug (75% for drug name con-
fusion and 89% for strength confusion). Also 14 pharmacists (other) noticed the alert at the
end of the day, at the final check and not during the dispensing process. The prevention of
dispensing the wrong drug as result of the alert, had occurred in 9% of the pharmacies of the
respondents who had noticed the alert for drug name confusion and 12% of the respondents
who had noticed the alert for strength confusion.
The respondents indicated that they were satisfied with the drug name confusion alerts
(Table 3). This varied between 97%, for dexamethasone and dexamfetamine, and 68% for
Table 3. Overview of the alerts for name and strength confusion and the proportion of respondents that is satisfied with the alert.
Drugs with an alert for drug name confusion
Would you like to receive an alert for drug name confusion for the following drugs? Yes; n, (%)
DexamethaSONe DexamphetAMINE 254 (96.6)
Tobrex (tobramycin) TobrADex (dexamethasone/tobramycin) 247 (94.3)
Fraxiparine1 (nadroparin) Fraxodi1 (nadroparin) 243 (92.0)
estrADiol Estriol 237 (90.1)
Modalim1 (ciprofibrate) Modafinil (Modiodal1) 229 (87.4)
Haloperidol injection Haloperidol decanoate injection (depot) 222 (84.7)
Povidone Povidone iodine eye drops 206 (78.9)
Hydrochlorothiazide 25 mg Hydroxyzine 25 mg 179 (68.1)
Are there any other drugs whereby you also want to receive an alert for drug name confusion? 77 (29.2)
Drugs with an alert for drug strength confusion
Would you like to receive an alert for strength and volume confusion for the following drugs? Yes; n, (%)
Pramipexole 0.375 mg Pramipexole 3.75 mg 237 (93.3)
Levothyroxine 12.5 μg Levothyroxine 125 μg 218 (85.8)
Haloperidol 0.5/1 mg Haloperidol 5/10 mg 198 (78.0)
Morphine 10 mg/ml– 1 ml Morphine 10 mg/ml– 10 ml 186 (73.2)
Morphine 20 mg/ml– 1 ml Morphine 20 mg/ml– 5 ml 183 (72.0)
Desmopressin 2.5/10 μg/do Desmopressin 150 μg/do 174 (68.5)
Oxazepam 5 mg Oxazepam 50 mg 162 (63.8)
Are there any other drugs whereby you also want to receive an alert for strength and volume confusion? 49 (19.3)
https://doi.org/10.1371/journal.pone.0197469.t003
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hydrochlorothiazide and hydroxyzine. Most respondents (71%) did not feel the need for more
alerts for drug name confusion. The most suggested drugs for an additional drug name confu-
sion alert were lormetazepam and lorazepam (n = 9), and oxycodon immediate versus sus-
tained release (n = 9). Also, the respondents indicated that they were satisfied with the alerts
for strength confusion (Table 3). This varied between 93% for pramipexole 0.375 mg and 3.75
mg, and 64% for oxazepam 5 mg and 50 mg. Most respondents (81%) did not experience a
need for more alerts for strength confusion. The most suggested drug for an additional drug
strength confusion alert was atropine (eye drops 0.01% vs 0.1% vs 1%) (n = 6).
Notability of the alerts
Most of the respondents thought that the alerts were notable (89% for drug name confusion,
82% for strength confusion) (Table 4). To make the alert for drug name confusion more nota-
ble, respondents suggested to mark the difference between the drug names in color. Also,
respondents commented that the pop-up window in the PIS was too small. Suggestions for
making the alert for strength confusion more notable were to make the numbers bold or in
color.
Tall man lettering was experienced as an improvement in the alerts for drug name confu-
sion by 94% of the respondents (Table 4), because this made the differences between the
names more distinctive and the alert more notable. Half of the respondents preferred Tall man
lettering in every alert for drug name confusions. Respondents who thought that Tall man let-
tering was not improving the alert commented that the plain letters forced you to read better.
Criteria for an alert for drug confusion
Most of the respondents preferred to receive an alert for drug name or strength confusion
(91%). Both the seriousness of the consequences (90%) as the frequency of the reported inci-
dents (82%) were factors that contributed to the need to prefer an alert. Respondents did not
necessarily want to receive an alert for every incident. Of the respondents, 45% found it suffi-
cient if the alert would only be received at the first dispensing. An important comment on the
questionnaire was that pharmacies indicated that the error is, most of the time, already made
during prescription by the primary care physician. Therefore, they thought it was important
that the alert would also be generated in the system of the prescribers.
Table 4. Pharmacist and technician’s attitude towards the alert for drug name and strength confusion and the use
of Tall man lettering.
Notability of the alerts. Drug name confusion
n, (%)
Strength confusion
n, (%)
Do you think the alert is striking? Yes: 236 (88.7) Yes: 211 (81.5)
Use of Tall man lettering.
Does the use of Tall man lettering make it easier to note an alert? Yes: 249 (94.0)
I would like to see Tall man lettering:
- For all alerts concerning drug name confusion. 133 (50.2)
- For drugs with the same memocodea. 71 (26.8)
- Only for drugs with a high risk of confusion. 48 (18.1)
- At no single alert for drug name confusion. 7 (2.6)
- Other 6 (2.3)
a Memocode is used to find the right drug easier and quicker in the PIS. A memocode in Pharmacom consist of the
first five letters of the drug followed by two or three numbers or letters corresponding to the administration form or
the strength (e.g. paracetamol tablet 500mg = PARAC 500).
https://doi.org/10.1371/journal.pone.0197469.t004
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Alert fatigue
About half of the respondents (52%) did not favor removing an alert for a specific drug if
there were no incidents due to drug confusion in the last year. The reason for this was that the
absence of incidences could have been due to the alert, and removal of the alert could reinstate
drug confusion. Moreover, respondents thought that alerts of confusions that caused serious
incidents should stay.
According to the additional comments (n = 35) that were given, ‘alert fatigue’ was an
important issue and this should be prevented. In the open answers respondents insisted they
preferred not (too) many alerts, as this increased the risk of alerts being ignored. However,
there was no maximum number of alerts for drug name or strength confusion because an alert
for each drug with a high risk for confusion and/or with serious consequences was desired.
Respondents indicated that there could be various reasons not to alert a drug name confusion
that resulted in a serious case (72%). The reason given most frequently was ‘an odd drug con-
fusion’, such as ‘bisoprolol—lisinopril’(36%).
Discussion
Pharmacies were satisfied with the alerts, and experienced that the alerts for drug name and
strength confusion contributed to the prevention of medication errors. This suggests that this
strategy of using alerts is useful in addition to other strategies, such as barcode scanning and
checking of the dispensing process by a colleague [7]. To minimize risks in complex processes
such as drug dispensing, a combination of safety measures was found to be most effective.
Since drug confusion is an important contributor to the drug dispensing error rate, implemen-
tation of alerts for drug name and strength confusion could significantly reduce this error rate
[3,8,26].
For three alerts, less than 70% of the respondents indicated they preferred to receive that
alert. A possible reason is the fear for ‘alert fatigue’, because these drugs (oxazepam and
hydrochlorothiazide) are regularly prescribed in the Netherlands. This indicates that an alert
for drug name and strength confusion is valuable, but that not every drug name or strength
confusion needs an alert. Therefore, it is necessary to determine the best strategy for the use
of these alerts. Selection criteria should be established about the implementation of new
alerts for drug confusion and removal of unnecessary alerts. Cases of name and strength con-
fusion and experiences of pharmacies and prescribers with alerts, including alert fatigue,
should be evaluated regularly (annually) to decide about the implementation of new alerts
and removal of alerts.
Pharmacies preferred to receive alerts for drugs where confusions occur frequently or are
associated with serious consequences. In the case of a non-serious incident or an odd confu-
sion an alert is not desired. However, the definition of an ‘odd confusion’, ‘frequent occur-
rence’ and ‘serious consequences’ is unclear.
The respondents experienced the notability of the alerts as sufficient and that the use of Tall
man lettering improved drug name confusion alerts. This is in accordance with other studies
that suggests that Tall man lettering makes similar names easier to distinguish [8,27]. Given
the positive experience with Tall man lettering, this should be used in the alerts for drug name
confusion. In the text of the alerts the specific drug names and the strengths that could be con-
fused were named. It remained unclear whether this information was useful. Further research
should investigate how the alerts should be presented in order to have the highest chance of
being noticed (Tall man lettering, larger pop-up window etc.).
This is the first study that evaluated alerts for drug name and strength confusion in the
PIS. In this study alerts for drug name and drug strength confusion were evaluated that were
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implemented in one of the PIS in the Netherlands, used by 60% of the pharmacies. A total of
269 people working in community pharmacy, both pharmacists and pharmacy technicians,
participated in this survey. However, this study has some limitations. Although this study had
a mean proportion of 22.3% respondents per pharmacy, the response rate is low compared to
the number of questionnaires that were sent, and response rates of from around 30% found
in other studies using web-based questionnaires [28–30]. Several reasons can explain this: the
email list was incomplete, the questionnaire was mailed to a general email address without
addressing the questionnaire to a responsible employee, and pharmacies might have unsub-
scribed to the newsletter. Another explanation might be that the alerts met the expectations,
as the results showed that the respondents were satisfied. Furthermore, only pharmacies that
had implemented the alert for drug confusion were investigated, and no other pharmacies or
prescribers. Hence, the results might not be representative for all pharmacies. Yet, given the
limitations, this study is a legitimate approach to expand the knowledge on preventing drug
confusion.
Further research should determine the interception rate (measure of the potential benefit
of the intervention) of alerts for drug name and strength confusion in the PIS is determined.
Such a study should demonstrate the actual effectiveness of the alerts on the dispensing error
rate. Also, future research should focus on prescribers: an alert for drug name and strength
confusion in the computerized prescribed order entry system will probably have additional
value to the current alert in the PIS.
Conclusion
Pharmacists and pharmacy technicians notice alerts for drug name and drug strength confu-
sion in their PIS and experience that these alerts contribute to the prevention of medication
errors. Alert fatigue is an important issue: pharmacies prefer to have an alert in case of confu-
sions that have been reported frequently, or were associated with serious safety incidents. It
was considered important not to include all possible confusions as a new alert.
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